Literature DB >> 2954587

Inactivation of atrial natriuretic factor by the renal brush border.

G M Olins, K L Spear, N R Siegel, H A Zurcher-Neely.   

Abstract

Atrial natriuretic factor (ANF), a 28-amino-acid peptide secreted from the mammalian heart, is known to be cleared rapidly from the circulation. In vitro and in vivo studies implicate the kidney as an important site for clearance and subsequent degradation of atrial natriuretic factor. We have observed that atrial natriuretic factor is inactivated rapidly by rabbit kidney brush-border membranes. The rate of degradation of ANF measured by the loss of bioactivity followed a similar time-course to the decrease in peptide peak area measured by high-performance liquid chromatography. Interestingly, inactivation of ANF produced only a single major degradation product, which was isolated and purified. Sequence analysis revealed that the product had the same sequence of amino acids as ANF with the Cys-7-Phe-8 bond cleaved and the disulfide bridge between Cys-7 and Cys-23 remaining intact. As the renal brush border contains an abundance of proteolytic activities, it is surprising that this peptide is cleaved primarily at a single peptide bond.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954587     DOI: 10.1016/0005-2736(87)90260-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance.

Authors:  C C Lang; T Moreland; A M Choy; T H Pringle; G P McNeill; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Natriuretic peptide metabolism, clearance and degradation.

Authors:  Lincoln R Potter
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

3.  Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.

Authors:  Deborah M Dickey; Lincoln R Potter
Journal:  J Mol Cell Cardiol       Date:  2011-04-01       Impact factor: 5.000

4.  Rapid receptor-mediated catabolism of 125I-atrial natriuretic factor by vascular endothelial cells.

Authors:  G R Johnson; L Arik; B J Pitts; C J Foster
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

5.  Ontogeny of atrial natriuretic peptide receptors in fetal rat kidney and adrenal gland.

Authors:  J N Scott; L H Jennes
Journal:  Histochemistry       Date:  1989

6.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.

Authors:  S H Fettner; S Pai; G R Zhu; T Kosoglou; C R Banfield; V Batra
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 7.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

8.  Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11.

Authors:  Z A Abassi; E Golomb; R Agbaria; P P Roller; J Tate; H R Keiser
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

9.  Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Authors:  C Gros; A Souque; J C Schwartz; J Duchier; A Cournot; P Baumer; J M Lecomte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

10.  Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog.

Authors:  A S Hollister; R J Rodeheffer; F J White; J R Potts; T Imada; T Inagami
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.